Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 | 5 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. It significantly enhances the activation and proliferation of T cells, inhibits migration and metastasis, and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. It can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Reduces the viability of specific cell lines
- Decreases the proportion of cells in the S phase
- Induces apoptosis in certain cell types
- Inhibits cell migration in multiple cell lines
- Reduces MCAM and N-cadherin expression
- Reduces the number and size of liver metastases in animal models
- Shows a trend toward reducing tumor volume in primary tumor sites in animal models
Medchemexpress LLC VMIP-II (1-21) TFA | 5 MG
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. It interacts broadly with CC and CXC chemokine receptors, inhibiting CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM). This product is for research use only and has not been fully validated for medical applications.
- Molecular formula: C108H169N33O27S.xC2HF3O2
- Sequence: Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro
- Target: CXCR
- Pathway: GPCR/G protein; immunology/inflammation
Medchemexpress LLC M65 TFA | 99.98% | 4823.53 (free base) | 1 MG
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with a deletion of residues between positions 24 and 42. It acts as a specific antagonist of the PACAP type 1 receptor, inhibiting ANP secretion, and can be utilized for relevant research purposes.
- Specific antagonist of the PACAP type 1 receptor.
- Inhibits ANP secretion.
- Suitable for research.
- In vitro activity: M65 (1 μM) completely blocks cAMP accumulation stimulated by 100 nM of VIP and partially inhibits cAMP accumulation stimulated by 1 nM of maxadilan in rat cortical neurons.
Medchemexpress LLC Dendrotoxin-I TFA | 99.1% | 7149.24 | 100 UG
Dendrotoxin-I TFA (DTX-I TFA) is a potent K+ channel blocker with IC50s of 0.13-50 nM for voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6. This neurotoxin demonstrates potential for cancer research and is intended for research use only.
- Potent K+ channel blocker: Exhibits IC50s of 0.13-50 nM against voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6.
- Neurotoxin with cancer research potential: Implicated in studies exploring its use in cancer research.
- In vivo activity: In an animal model using nude mice with MCF-7 cells, it showed a significant tumor growth inhibition effect when combined with hyperthermia.
Medchemexpress LLC Peptide R TFA | 98.3% | 900.08 | 5 MG
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. It exhibits outstanding capacities to remodel the tumor stroma and can be used for solid tumor research, including glioblastoma.
- Synthetic and specific CXCR4 antagonist
- Exhibits outstanding capacities to remodel the tumor stroma
- Can be used for solid tumor research, including glioblastoma
- Molecular weight is 900.08 (free base)
- Appears as a white to off-white solid
- Sequence is Arg-Ala-Cys-Arg-Phe-Phe-Cys with a disulfide bridge at Cys3-Cys7
Medchemexpress LLC MC-VC-PAB-NH2 TFA | 1616727-21-9 | 99.9% | 772.77 | 1 MG
MC-VC-PAB-NH2 TFA is a cleavable antibody-drug conjugate (ADC) linker, utilized in the synthesis of ADCs. ADCs are composed of an antibody to which an ADC cytotoxin is attached via an ADC linker.
- Cleavable antibody-drug conjugate linker
- Utilized in the synthesis of ADCs
- High purity of 99.9%
- Appears as a white to off-white solid
- Protease cleavable
Medchemexpress LLC Achn-975 Tfa | 1410809-37-8 | 99.0% | 483.44 | 25 MG
ACHN-975 TFA is a selective LpxC inhibitor that demonstrates subnanomolar LpxC inhibitory activity. It is effective against a broad spectrum of gram-negative bacteria, exhibiting low MIC values (≤1 μg/mL).
- Selective LpxC inhibitor
- Exhibits subnanomolar LpxC inhibitory activity
- Effective against a wide range of gram-negative bacteria with low MIC values (≤1 μg/mL)
- Potent against *P. aeruginosa* isolates
- Demonstrates bactericidal activity against *P. aeruginosa* ATCC27853 strain in vivo.
Medchemexpress LLC Tfllr-nh2(tfa) | 1313730-19-6 | 99.6% | 761.83 | 50 MG
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM. It is for research use only and not sold to patients.
- Functions as a selective PAR1 agonist.
- Stimulates concentration-dependent increases in intracellular calcium.
- Modulates E-cadherin and vimentin expression in SW620 cells.
- Induces edema in rat paw models.
- Stimulates Evans blue extravasation in various mouse tissues.
- Exhibits both contraction and relaxation effects.
Medchemexpress LLC 6bK (TFA) | 1774353-12-6 | MFCD30182289 | 99.4% | 871.94 g/mol | C43H56F3N7O9 | 5 MG
6bK TFA is a potent, selective insulin-degrading enzyme (IDE) inhibitor used in preclinical research to study insulin metabolism and glucose tolerance. It shows an in vitro IC50 of approximately 50 nM and has been reported to increase circulating insulin and improve oral glucose tolerance in high-fat-fed mice.
- Potent IDE inhibition (IC50 ≈ 50 nM).
- Selective activity for insulin-degrading enzyme.
- High purity (≈99.4%).
- Available as solid and DMSO solution in multiple pack sizes.
- Supplied with analytical documents (COA, HPLC, LCMS).
- Recommended storage: solid -20°C; in solvent -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC Lys-bradykinin trifluoroacetate | 00-00-0 | 99.9% | 1188.38 g/mol | C56H85N17O12·xC2HF3O2 | 100 MG
Lys-Bradykinin TFA is the trifluoroacetate salt of the decapeptide kallidin (Lys-bradykinin), supplied as a purified peptide powder for laboratory research. It acts as a ligand for kallidin and bradykinin receptors and is involved in vascular regulation, inflammation, and pain signaling.
- TFA salt of Lys-bradykinin (kallidin).
- Decapeptide sequence: Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg.
- High purity (99.9%).
- Molecular weight 1188.38 g/mol (free base).
- Storage: powder - sealed, away from moisture and light; powder storage: -80°C for 2 years, -20°C for 1 year.
Medchemexpress LLC Boc-Met-Leu-Phe (trifluoroacetate) | 00-00-0 | MFCD00037435 | 99.5% | 623.68 g/mol | C27H40F3N3O8S | 1 ML
Boc-MLF TFA is a Boc-protected tripeptide (Boc-Met-Leu-Phe as the trifluoroacetate salt) used as a formyl peptide receptor (FPR) antagonist for receptor pharmacology and cell signaling studies. It is supplied as a 10 mM solution in DMSO (1 mL) or as a dry powder and is offered with high reported purity for research applications.
- Acts as a formyl peptide receptor (FPR) antagonist.
- Inhibits formyl peptide receptor like 1 (FPRL1) at higher concentrations.
- Available as a 10 mM solution in DMSO (1 mL) or as dry powder formats.
- High reported purity suitable for biochemical assays (~99.5%).
- Contains Boc-protected Met-Leu-Phe sequence as the trifluoroacetate salt.
Medchemexpress LLC Ss47 Tfa | 2636072-62-1 | 99.88% | 1067.09 | 1 MG
SS47 TFA is a PROTAC-based HPK1 degrader that facilitates proteasome-mediated HPK1 degradation. This significantly improves in vivo antitumor efficacy in BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies. SS47 (TFA) is also a click chemistry reagent with an Alkyne group, capable of copper-catalyzed azide-alkyne cycloaddition (CuAAc).
- PROTAC-based HPK1 degrader
- Facilitates proteasome-mediated HPK1 degradation
- Enhances in vivo antitumor efficacy in BCMA CAR-T cell research
- Targets HPK1, an immunosuppressive regulatory kinase
- Click chemistry reagent with alkyne group
- Capable of copper-catalyzed azide-alkyne cycloaddition (CuAAc)